Sentinel Lymph Node Mapping In Malignant Melanoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for sentinel lymph node mapping in malignant melanoma. 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
5
Active US patents
67/100
Avg vulnerability
—
Annual revenue covered

Originators in Sentinel Lymph Node Mapping In Malignant Melanoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Renew Pharms 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating sentinel lymph node mapping in malignant melanoma. Each bar = one year. Y-axis scaled to peak year (2 patents).

1
28
2
29
1
35
1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Spy Agent Green Kit
INDOCYANINE GREEN
 Renew Pharms 5 67 — 2028-06-04

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8185176 Spy Agent Green Kit method of use 75 2028-06-04
8647605 Spy Agent Green Kit method of use 75 2029-02-11
8406860 Spy Agent Green Kit method of use 75 2029-04-09
10631746 Spy Agent Green Kit method of use 62 2035-08-04
11712320 Spy Agent Green Kit formulation 50 2039-07-14

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11712320 Spy Agent Green Kit formulation 50 2039-07-14
10631746 Spy Agent Green Kit method of use 62 2035-08-04
8406860 Spy Agent Green Kit method of use 75 2029-04-09
8647605 Spy Agent Green Kit method of use 75 2029-02-11
8185176 Spy Agent Green Kit method of use 75 2028-06-04

Related